The New York Times continues to be the best and brightest remaining light for good national journalism. I can’t speak to your politics; I’m impressed with the depth and breadth of the medical writing. I don’t see that as political.
The FDA just approved yet another new, late stage melanoma therapy, nivolumab. That makes a record, mind blowing seven new FDA approved drugs since 2011.
This is exciting news. Not so much because of this specific new drug. But because of what it represents: cancer immunotherapy is becoming a reality.
I saved this interesting article that I read in HealthDay.com to share with you:
I saved this article about some important news concerning Omega-3 fatty oils and skin cancer. Check it out this excerpt:
Skin cancer is by far the most common form of cancer. In the U.S., there will be over one million cases diagnosed this year alone.
Having recently had an area of melanoma removed from my left ear, this story caught my attention.
Talk about scary…
Here is a fascinating, yet bizare story I found in the New York Daily News…
Here is the opening few paragraphs of a story I found on the Cancer/MSNBC,com site:
Here is solid, scientific proof that using sunscreen helps prevent cancer:
Did you see the story about another new melanoma wonder drug this morning on NBC’s The Today Show? Here is the introduction to a companion Reuters story running on MSNBC.com:
Technical difficulties with the Blogger network prevented me from posting any articles or links today–until now.
One of our readers, Bob, alerted me to this excellent article in the New York Times about a new melanoma drug, PLX4032. Here is a short excerpt from that February 22, 2010 article:
Just saw this today. Another possible cancer fighting tool?
New research shows higher levels of vitamin D may help improve survival for both bowel and skin cancer patients, according to a September 22nd article in Medical News Today.Com.
The results of two studies published in the British Journal of Cancer and Journal of Clinical Oncology found people with higher levels of vitamin D – at the time they were diagnosed – were more likely to survive.
In the first study researchers from the Dana-Farber Cancer Institute, Boston followed 1017 bowel cancer patients for around nine years.
Using information about UV-B and sunlight exposure, skin type, body-mass index, and vitamin D intake from food and supplements they estimated the amount of vitamin D in patients’ blood at the time of diagnosis.
The results showed that those with higher vitamin D scores after being diagnosed with cancer were 50 per cent less likely to die from the disease – compared to those with lower vitamin D scores.
Professor Kimmie Ng, study author, said: “Our study shows that levels of vitamin D after colorectal cancer diagnosis may be important for survival. We are now planning further research in patients with bowel cancer to see if vitamin D has the same effect, and to investigate how vitamin D works with molecular and genetic pathways in the cell to fight cancer.”